Utility of health states in chronic kidney disease: A structured review of the literature

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 193-206

  Dale, Peter L ^a   Hutton, J ^a   Elgazzar, H ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Genzyme Corp   (United Kingdom)

Author keywords

Chronic kidney disease; Health related quality of life; Quality of life; Quality adjusted life years; Renal failure, chronic; Utility, cost

Indexed keywords

CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ECONOMIC ASPECT; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HEMODIALYSIS; HUMAN; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; REVIEW; UNITED KINGDOM;

GREAT BRITAIN; HEALTH CARE COSTS; HEALTH STATUS INDICATORS; HUMANS; MODELS, ECONOMIC; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN;

EID: 38549105551     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X253410     Document Type: Review

References (60)

1. Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician 2004;70:869-76
2. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331-40
3. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States renal data system 2006 annual data report. Am J Kidney Dis 2007;49(Suppl 1):A6-7, S1-S296
4. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12
5. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-93
6. Bakewell AB, Higgins RM, Edmunds ME. Quality of life in peritoneal dialysis patients: decline over time and association with clinical outcomes. Kidney Int 2002;61:239-48
7. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8
8. Mingardi G. From the development to the clinical application of a questionnaire on the quality of life in dialysis. The experience of the Italian Collaborative DIA-QOL (Dialysis-Quality of Life) Group. Nephrol Dial Transplant 1998;13(Suppl 1):70-5
9. Gudex CM. Health-related quality of life in end stage renal failure. Qual Life Res 1995;4:359-66
10. de Wit GA, Merkus MP, Krediet RT, de Charro FT. Health profiles and health preferences of dialysis patients. Nephrol Dial Transplant 2002;17:86-92
11. Hays RD, Kellich JD, Mapse DL, et al. Kidney disease and quality of life short form (KDQOL-SF™), version 1.1: a manual for use and scoring. Santa Monica: RAND; 1995. p. 7928
12. Razvi S, McMillan CV, Weaver JU. Instruments used in measuring symptoms, health status and quality of life in hypothyroidism: a systematic qualitative review. Clin Endocrinol 2005;63:617-24
13. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
14. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787-805
15. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9
16. Gold MR, Siegel JE, Russell LB. Cost effectiveness in health and medicine. New York (NY): Oxford University press; 1996
17. Anon. Guide to the methods of technology appraisal (reference N0515) 7 May 2004. National Institute for Health and Clinical Excellence (NICE), London, UK. Available at www.nice.org.uk/page.aspx?o=201973 [last accessed 1 June 2007]
18. Brooks R, EuroQol Group. EuroQol: the current state of play. Health Policy 1996;37:53-72
19. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
20. Feeny DH, Furlong WJ, Torrance GW, et al. Multi-attribute and single-attribute utility function: the Heath Utility Index Mark 3 system. Med Care 2002;40:113-28
21. Brazier J, Roberts J, Deverill M. The estimation of a preference-based single index measure for health from the SF-36. J Health Economics 2002;21:271-92
22. Kaplan RM, Bush JW, Berry CC. Health status index: category rating versus magnitude estimation for measuring levels of well-being. Med Care 1979;17:501-25
23. Sennfalt K, Magnusson M, Carlsson P. Comparison of haemodialysis and peritoneal dialysis - a cost-utility analysis. Peritoneal Dial Int 2002;22:39-47
24. Manns B, Johnson JA, Taub K, et al. Quality of life in patients treated with haemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 2003;60:341-51
25. Bass EB, Wills S, Fink NE, et al. How strong are patients' preferences in choices between dialysis modalities and doses? Am J Kidney Dis 2004;44:695-705
26. Groome PA, Hutchinson TA, Tousignant P, Hanley JA. The repeatability of three methods for measuring prospective patients' values in the context of treatment choice for end-stage renal disease. J Clin Epidemiol 1999;52:849-60
27. Arredondo A, Rangel R, de Icaza E. Cost-effectiveness of interventions for end-stage renal disease. Revista de Saude Publica 1998;32:556-65
28. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32
29. Molzahn AE, Northcott HC, Hayduk L. Quality of life of patients with end stage renal disease: a structural equation model. Qual Life Res 1996;5:426-32
30. Churchill DN, Torrance GW, Taylor DW, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987;10:14-20
31. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573-8
32. Revicki DA. Relationship between health utility and psychometric health status measures. Med Care 1992;30 (Suppl 5):MS274-MS282
33. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics 1992;1:346-56
34. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. Br Med J 1995;311:1595-9
35. Douzdjian V, Ferrara D, Silvestri G. Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model. Am J Kidney Dis 1998;31:794-802
36. Postulart D, Adang EM. Response shift and adaptation in chronically ill patients. Med Decis Making 2000;20:186-93
37. Holohan TV. Cost-effectiveness modeling of simultaneous pancreas-kidney transplantation. Int J Technol Assess Health Care 1996;12:416-24
38. Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation - a prospective study. Transplantation 1992;54:656-60
39. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-42
40. Greiner W, Obermann K, Schulenburg JM. Socio-economic evaluation of kidney transplantation in Germany. Arch Hell Med 2001;18:147-55
41. de Wit GA, Merkus MP, Krediet RT, de Charro FT. A comparison of quality of life of patients on automated and continuous ambulatory peritoneal dialysis. Peritoneal Dial Int 2001;21:306-12
42. Kontodimopoulos N, Niakas D. Overcoming inherent problems of preference-based techniques for measuring health benefits: an empirical study in the context of kidney transplantation. BMC Health Serv Res 2006;6:3
43. Molzahn AE, Northcott HC, Dossetor JB. Quality of life of individuals with end stage renal disease: perceptions of patients, nurses, and physicians. ANNA J 1997;24:325-33 [discussion 334-5]
44. Lawrence WF, Grist TM, Brazy PC. Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis 1995;25:701-9
45. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7
46. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian haemodialysis. Am J Kidney Dis 2003;42(Suppl 1):36-41
47. Rasanen P, Roine E, Sintonen H, et al. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 2006;22:235-41
48. Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005;8:3-9
49. Veenhoven R. Happy life-expectancy. A comprehensive measure of quality-of-life in nations. Soc Indicators Res 1996;39:1-58
50. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke: a comprehensive review. Stroke 2001;32:964-72
51. Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004;9:43-50
52. Lenert LA, Treadwell JR, Schwartz CE. Associations between health status measures and utilities: implications for policy. Medical Care 1999;37:479-89
53. Churchill DN, Wallace JE, Ludwin D, et al. A comparison of evaluative indices of quality of life and cognitive function in haemodialysis patients. Control Clin Trials 1991;12(Suppl 4):159S-167S
54. Churchill DN, Bird DR, Taylor DW, et al. Effect of high-flux haemodialysis on quality of life and neuropsychological function in chronic haemodialysis patients. Am J Nephrol 1992;12:412-8
55. Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults [SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments]. Ann Intern Med 1997;127:195-202
56. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992;45:505-12
57. Lenert LA, Hornberger JC. Computer-assisted quality of life assessment for clinical trials. Proc AMIA Annu Fall Symp 1996;1:992-6
58. Maor Y, King M, Olmer L, Mozes B. A comparison of three measures: the time trade-off technique, global health-related quality of life and the SF-36 in dialysis patients. J Clin Epidemiol 2001;54:565-70
59. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional in-centre haemodialysis. Kidney Int 2003;64:1004-11
60. Sesso R, Yoshihiro MM. Time of diagnosis of chronic renal failure and assessment of quality of life in haemodialysis patients. Nephrol Dial Transplant 1997;12:2111-6